Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.48 |
| ▸ | MDM4 | O15151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12510929 | 1.00 | CASP3 (0.48) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL12744189 | 0.88 | MDM4 (0.52) | CASP3MDM4TP53KMT2AKIF11 | |
| SCHEMBL3212833 | 0.88 | MDM4 (0.52) | CASP3MDM4TP53KMT2AKIF11 | |
| SCHEMBL24378419 | 0.87 | CASP3 (0.48) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL13424243 | 0.87 | MDM4 (0.51) | CASP3MDM4TP53KMT2A | |
| SCHEMBL12934191 | 0.87 | MDM4 (0.51) | CASP3MDM4TP53KMT2A | |
| SCHEMBL1738641 | 0.87 | MDM4 (0.55) | CASP3MDM4TP53KMT2A | |
| SCHEMBL5998507 | 0.87 | MDM4 (0.55) | CASP3MDM4TP53KMT2A | |
| SCHEMBL29560536 | 0.87 | MDM4 (0.55) | CASP3MDM4TP53KMT2A | |
| SCHEMBL29503847 | 0.87 | MDM4 (0.55) | CASP3MDM4TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178700-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20090047711-A1 | BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS | AILERON THERAPEUTICS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047711-A1 | BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS | CBS, HLCS, CTH | CASP3 2522/4885MDM4 3300/4885TP53 1820/4885 |
| US-20120178700-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | CASP3 1026/4885MDM4 3015/4885TP53 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.